{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:58:46Z","timestamp":1767988726365,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.clgc.2017.10.025","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:01:48Z","timestamp":1512172908000},"page":"e491-e496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy"],"prefix":"10.1016","volume":"16","author":[{"given":"Juan","family":"Morote","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inma","family":"Comas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Planas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Celma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Placer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roser","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Carles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Regis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2017.10.025_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.10.025_bib2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM198411153112004","article-title":"Leuprolide versus diethylstilbestrol for metastatic prostate cancer","volume":"311","author":"The Leuprolide Study Group","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.10.025_bib3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0090-4295(00)00793-7","article-title":"Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making","volume":"56","author":"Oefelein","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2017.10.025_bib4","first-page":"1290","article-title":"Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy","volume":"178","author":"Morote","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.10.025_bib5","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1373\/49.8.1381","article-title":"Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children","volume":"49","author":"Taieb","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.clgc.2017.10.025_bib6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1210\/jc.2003-031287","article-title":"Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry","volume":"89","author":"Wang","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2017.10.025_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1210\/jc.2006-1864","article-title":"Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement","volume":"92","author":"Rosner","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2017.10.025_bib8","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1210\/jc.2010-1314","article-title":"Toward excellence in testosterone testing: a consensus statement","volume":"95","author":"Rosner","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2017.10.025_bib9","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1373\/clinchem.2010.143222","article-title":"Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals","volume":"56","author":"Kushnir","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.clgc.2017.10.025_bib10","series-title":"EP28\u2013A3: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Proposed Guideline","author":"Horowitz","year":"2010"},{"key":"10.1016\/j.clgc.2017.10.025_bib11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eursup.2007.04.001","article-title":"Optimal testosterone control and Eligard\u00ae","volume":"6","author":"Tombal","year":"2007","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clgc.2017.10.025_bib12","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0149-2918(02)80087-X","article-title":"A\u00a0six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer","volume":"24","author":"Perez-Marreno","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.clgc.2017.10.025_bib13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.clinthera.2010.04.013","article-title":"Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a phase III, open-label, international multicenter study","volume":"32","author":"Marberger","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clgc.2017.10.025_bib14","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2017.10.025_bib15","first-page":"1601","article-title":"Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry","volume":"187","author":"van der Sluis","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.10.025_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.2009.08814.x","article-title":"Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?","volume":"105","author":"Perachino","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2017.10.025_bib17","doi-asserted-by":"crossref","first-page":"E500","DOI":"10.1111\/j.1464-410X.2012.11190.x","article-title":"Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?","volume":"110","author":"Pickles","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2017.10.025_bib18","doi-asserted-by":"crossref","first-page":"E263","DOI":"10.5489\/cuaj.471","article-title":"Defining a new testosterone threshold for medical castration: results from a prospective cohort series","volume":"7","author":"Dason","year":"2013","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2017.10.025_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clgc.2013.01.002","article-title":"Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer","volume":"11","author":"Bertaglia","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2017.10.025_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/iju.12623","article-title":"Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade?","volume":"22","author":"Yasuda","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2017.10.025_bib21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"33","author":"Klotz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.10.025_bib22","first-page":"1264","article-title":"Nadir testosterone after long-term follow-up predicts prognosis of prostate cancer patients treated with combined androgen blockade","volume":"194","author":"Kamada","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.10.025_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.acuro.2016.01.006","article-title":"Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: a systematic review","volume":"40","author":"Morote","year":"2016","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.clgc.2017.10.025_bib24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/iju.13180","article-title":"Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy","volume":"23","author":"Morote","year":"2016","journal-title":"Int J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317303415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317303415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:28:17Z","timestamp":1761564497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767317303415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1558767317303415"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2017.10.025","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2017.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}